country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-187939

Copy Link Print Information

GT-055 free base

Name: GT-055 free base
Brand: MedChemExpress
SKU: HY-187939
Availability: PreOrder

(Synonyms: LCB18-055 free base)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

GT-055 free base (LCB18-055 free base) is a broad-spectrum β-lactamase inhibitor and penicillin-binding protein 2 (PBP2) inhibitor. GT-055 free base inactivates β-lactamase, protects GT-1 from hydrolysis, and binds tightly to PBP2, thereby inhibiting cell wall biosynthesis. GT-055 free base can be used for research on bacterial infections.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 2092930-66-8
Formel: C₁₁H₁₉N₅O₆S
Molecular Weight:349.36

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

GT-055 free base Chemical Structure

CAS. Nr.: 2092930-66-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen :

In Vitro

GT-055 (0.12-256 µg/mL) free base exhibits intrinsic antibacterial activity against E. coli panel strains with MICs of 2 to 8 µg/mL^[2].
GT-055 (0.12-256 µg/mL) free base lacks intrinsic antibacterial activity against Acinetobacter spp. panel strains with MIC > 256 µg/mL^[2].
GT-055 (0.12-256 µg/mL) free base exhibits intrinsic antibacterial activity against most K. pneumoniae panel strains with MICs of 2 to 8 µg/mL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GT-055 (30-120 mg/kg; co-administered with GT-1 at a 1:1 ratio via subcutaneous injection; once every 6 h; 21 days) free base treats B. pseudomallei-infected mice, producing a maximum survival rate of 30% and failing to persistently clear the bacterial burden in the spleen^[1].
GT-055 (20-200 mg/kg; co-administered with GT-1 at a 1:1 ratio via subcutaneous injection; once every 6 h; 7 days) free base combination therapy is highly effective against Y. pestis in a murine intranasal infection model, achieving 80% and 100% survival rates at doses of 60/90 mg/kg and 200/300 mg/kg, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c (female, 6-8 weeks old, infected with Burkholderia pseudomallei strain 1026b via aerosol)^[1]
Dosage:

30/30 mg/kg (GT-1/GT-055, initiated 12 h post-infection); 60/60 mg/kg (GT-1/GT-055, initiated 12 h post-infection); 120/120 mg/kg (GT-1/GT-055, initiated 12 h post-infection); 120/120 mg/kg (GT-1/GT-055, initiated 6 h post-infection)
Administration:

s.c.; q6h; 21 days
Result:

Achieved 10% survival with a median survival of 10.5 days at 30/30 mg/kg.
Achieved 0% survival with a median survival of 14.5 days at 60/60 mg/kg.
Achieved 30% survival with a median survival of 42.5 days at 120/120 mg/kg initiated at 12 h post-infection.
Achieved 10% survival with a median survival of 42.5 days at 120/120 mg/kg initiated at 6 h post-infection.
Showed 0 CFU/spleen in surviving mice at 120/120 mg/kg initiated at 12 h post-infection.
Showed 1.34 × 10⁸ CFU/spleen in one survivor at 30/30 mg/kg.
Showed 9.50 × 10⁸ CFU/spleen in one survivor at 120/120 mg/kg initiated at 6 h post-infection.

Animal Model:

BALB/c (female, 6-8 weeks old, infected with Yersinia pestis strain CO92 via intranasal inoculation)^[1]
Dosage:

20/30 mg/kg; 60/90 mg/kg; 200/300 mg/kg
Administration:

s.c.; q6h; 7 days
Result:

Resulted in 0% survival at 20/30 mg/kg.
Resulted in 80% survival at 60/90 mg/kg.
Resulted in 100% survival at 200/300 mg/kg.
Showed 0 CFU/g spleen and lung bacterial loads of 13.1 × 10³, 21.1 × 10³, and 0 CFU/g in 3 surviving mice at 60/90 mg/kg.
Showed 0 CFU/g spleen and lung bacterial loads of 18.7 × 10³, 0, and 0 CFU/g in 3 surviving mice at 200/300 mg/kg.

Chemical Information

CAS. Nr. 2092930-66-8
Molecular Weight 349.36
Formel C₁₁H₁₉N₅O₆S
SMILES

O=C1[N@]2[C@H](C3=NOC(CN)(CN)C3)CC[C@](N1OS(=O)(O)=O)([H])C2
Synonyms

LCB18-055 free base
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (1)

All

Sort by:

Journal Impact Factor

Pharmaceuticals (Basel)

β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources. [Abstract]

2022 Apr 13;15(4):476. PMID: 35455473

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Halasohoris SA, et al. In vitro and in vivo activity of GT-1, a novel siderophore cephalosporin, and GT-055, a broad-spectrum β-lactamase inhibitor, against biothreat and ESKAPE pathogens. The Journal of antibiotics. 2021 Dec;74(12):884-892. [Content Brief]

[2]. Nguyen LP, et al. In Vitro Activity of a Novel Siderophore-Cephalosporin, GT-1 and Serine-Type β-Lactamase Inhibitor, GT-055, against Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. Panel Strains. Antibiotics (Basel). 2020 May 20;9(5):267.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

GT-055 free base

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

GT-055 free base

Publications Citing Use of MedChemExpress (MCE) GT-055 free base

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen